MRUS Merus N.V.

Merus BV is a clinical stage immuno-oncology company. It is engaged in developing bispecific antibody therapeutics.

$26.22  +1.43 (5.75%)
As of 12/07/2021 15:59:55 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  The Netherlands
Country of incorporation:  The Netherlands
IPO date:  05/19/2016
Outstanding shares:  38,811,963
Average volume:  234,478
Market cap:   $957,491,127
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    N5749R100
ISIN:        NL0011606264
Valuation   (See tab for details)
PE ratio:   -11.97
PB ratio:   4.65
PS ratio:   22.05
Return on equity:   -39.05%
Net income %:   -185.10%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy